Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
OpenAI Rejects Apple Trade Secret Theft Claims 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Add as a preferred source on Google
VANCOUVER, British Columbia, March 05, 2018 -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, will report its financial results for the year ending December 31, 2017 and will provide a general business update on Monday March 12, 2018 after U.S. markets close.
Conference Call and Webcast Details:
Date: Monday March 12, 2018
Time: 4:30 PM (ET) / 1:30 PM (PT)
Toll-free: (866) 357-7878
International: (315) 625-3088
Audience Passcode 4665267
Webcast URL: https://edge.media-server.com/m6/p/9vvkbdes
The live webcast may be accessed through the "Events & Presentations" page in the "Investor Relations" section of the company's website at www.aqxpharma.com. The archived webcast will also be available on Aquinox's website approximately two hours after the event and will be available for replay for at least 30 days after the event.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is a first-in-class, once-daily, oral treatment with a novel mechanism of action, activating SHIP1 (SH2-containing inositol-5'-phosphatase 1), an enzyme that serves to down-regulate inflammation through its role in the PI3K signaling pathway. Rosiptor is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a debilitating condition marked by chronic bladder pain and urinary symptoms, for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.
Contact Info:
| Brendan Payne Associate Director, Investor Relations Aquinox Pharmaceuticals, Inc. 604.901.3019 [email protected] | Bill Kadel Vice President Solebury Trout 646.378.2934 [email protected] |
